Skip to Main content Skip to Navigation
Journal articles

Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2

Abstract : Repurposing drugs as treatments for COVID-19, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has drawn much attention. Beginning with sigma receptor ligands and expanding to other drugs from screening in the field, we became concerned that phospholipidosis was a shared mechanism underlying the antiviral activity of many repurposed drugs. For all of the 23 cationic amphiphilic drugs we tested, including hydroxychloroquine, azithromycin, amiodarone, and four others already in clinical trials, phospholipidosis was monotonically correlated with antiviral efficacy. Conversely, drugs active against the same targets that did not induce phospholipidosis were not antiviral. Phospholipidosis depends on the physicochemical properties of drugs and does not reflect specific target-based activities—rather, it may be considered a toxic confound in early drug discovery. Early detection of phospholipidosis could eliminate these artifacts, enabling a focus on molecules with therapeutic potential.
Document type :
Journal articles
Complete list of metadata

https://hal-pasteur.archives-ouvertes.fr/pasteur-03696873
Contributor : Isma Ziani Connect in order to contact the contributor
Submitted on : Thursday, June 16, 2022 - 11:51:16 AM
Last modification on : Saturday, June 18, 2022 - 4:05:16 AM

File

science.abi4708.pdf
Publication funded by an institution

Licence


Distributed under a Creative Commons Attribution 4.0 International License

Identifiers

Collections

Citation

Tia A. Tummino, Veronica V. Rezelj, Benoit Fischer, Audrey Fischer, Matthew J. O’meara, et al.. Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2. Science, American Association for the Advancement of Science (AAAS), 2021, 373 (6554), pp.541-547. ⟨10.1126/science.abi4708⟩. ⟨pasteur-03696873⟩

Share

Metrics

Record views

0

Files downloads

0